Cellular Immunotherapy Market to Grow with a CAGR of 9.31% through 2028

Rising prevalence of cancer are expected to drive the Global Cellular Immunotherapy Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Cellular Immunotherapy Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Cellular Immunotherapy Market stood at USD 6.43 Billion in 2022 and is anticipated to grow with a CAGR of 9.31% through 2028. The rising prevalence of cancer is another impact rendering factor for the growth. According to Globocan estimates, in 2020, an estimated 19.2 million new cancer cases were reported worldwide and this number is projected to reach 24.5 million by 2030. In 2020, cancer accounted for an estimated 10 million deaths. According to Cancer Research U.K., more than 375,000 new cancer cases are reported each year in the U.K. Also, based on WHO estimates, two-thirds of the population aging 60 years & above live in developing countries. Aging is the most common factor that increases the risk of cancer. Therefore, the rising geriatric population is expected to increase the prevalence during the forecast period, which will drive the demand for cellular immunotherapies. However, the high cost of cellular immunotherapy product manufacturing is expected to restrain the growth. Cellular immunotherapy involves modified immune cells that make them more sensitive to differentiate between healthy and cancer tissues. The manufacturing process is complicated and expensive. The need for high capital investment, a highly aseptic environment, and the presence of significant operational difficulties are some of the factors that raise the cost of cellular immunotherapy manufacturing, thereby increasing the overall cost of the therapy.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Cellular Immunotherapy Market”

The Global Cellular Immunotherapy Market is segmented into Therapy Type, Indication, Indication, and company.

Based on the Indication, the B-cell Malignancies segment is anticipated to witness substantial market growth throughout the forecast period. The growth of the Global Cellular Immunotherapy Market is anticipated to be significantly propelled by the treatment of B-cell malignancies. Cellular immunotherapy, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies, has demonstrated remarkable efficacy in addressing B-cell malignancies such as certain types of leukemia and lymphomas. These therapies involve the genetic modification of a patient's T cells to express chimeric receptors, enabling them to recognize and eliminate B-cell cancers with precision. The specificity of cellular immunotherapy for B-cell malignancies addresses a critical unmet medical need, especially in cases resistant to conventional treatments. The success of CAR-T therapies in achieving deep and durable responses in patients with relapsed or refractory B-cell malignancies has positioned these interventions as groundbreaking treatments.

Based on the End-Use segment, the Hospital Pharmacies segment has been the dominant force in the market. Cancer institutes are poised to play a pivotal role in propelling the growth of the Global Cellular Immunotherapy Market. These specialized institutions, dedicated to advancing cancer research and treatment, serve as epicenters for innovation, collaboration, and clinical trials focused on cellular immunotherapies. Their expertise in understanding the intricacies of cancer biology and their access to diverse patient populations position cancer institutes as critical players in driving advancements in cellular immunotherapy. Collaborative efforts between cancer institutes and biopharmaceutical companies foster the development of novel cellular immunotherapies. The infrastructure and resources within these institutes accelerate the translation of groundbreaking research into clinical applications, expediting the pathway to regulatory approvals and commercialization. Moreover, cancer institutes often serve as hubs for training healthcare professionals in the administration and management of cellular immunotherapies, ensuring widespread adoption and dissemination of best practices. Their influence extends beyond research and development, as they contribute to shaping treatment guidelines and protocols, influencing regulatory decisions, and raising awareness about the transformative potential of cellular immunotherapy.

Major companies operating in Global Cellular Immunotherapy Market are:

• Bristol-Myers Squibb Company.
• Novartis AG.
• Gilead Sciences Inc. (Kite Pharma)
• F. Hoffmann-La Roche Ltd.
• Merck KGaA.
• GlaxoSmithKline plc.
• AstraZeneca Plc.
• Pfizer Inc.
• Johnson & Johnson.
• Celyad.

Download Free Sample Report

Customers can also request 10% free customization on this report

“Some of the major factors propelling the market growth are the development of advanced cell-based therapies, the rising prevalence of cancer, and increasing R&D investment by key companies. Moreover, the increasing number of product approvals and growing adoption of these therapies for the treatment of cancer is boosting the market growth. Aging is the most common factor that increases the risk of cancer. Therefore, the rising geriatric population is expected to increase the prevalence during the forecast period, which will drive the demand for cellular immunotherapies. However, the high cost of cellular immunotherapy product manufacturing is expected to restrain the growth. Cellular immunotherapy involves modified immune cells that make them more sensitive to differentiate between healthy and cancer tissues. The manufacturing process is complicated and expensive.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Cellular Immunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others), By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others), By End-Use (Hospitals, Cancer Institutes, Others), By Region, By Competition”, has evaluated the future growth potential of Global Cellular Immunotherapy  Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Cellular Immunotherapy Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]